{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T15:25:41Z","timestamp":1751642741730,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijantimicag.2024.107345","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T16:01:43Z","timestamp":1727107303000},"page":"107345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges and potential solutions for cycloserine dosing in patients with sepsis undergoing continuous renal replacement therapy"],"prefix":"10.1016","volume":"64","author":[{"given":"Ruoying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junke","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-3610","authenticated-orcid":false,"given":"Jinmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107345_bib0001","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130 Suppl 1","author":"Vanino","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0002","first-page":"481","article-title":"Expert consensus on perioperative management of elderly septic patients","volume":"12","author":"Jiren","year":"2021","journal-title":"Med J Peking Union Medical College Hospital"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028019865873","article-title":"Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update","volume":"54","author":"Hoff","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0004","first-page":"533","article-title":"Beijing Chest Hospital, Capital Medical University clinical Trial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis","volume":"42","year":"2020","journal-title":"Chin J Antituberc"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0005","first-page":"658","article-title":"Meter-analysis of effectiveness and safety of the cycloserine-containing treatment for multidrug-resistant pulmonary tuberculosis in China","volume":"45","author":"Rui","year":"2023","journal-title":"Chin J Antituberc"},{"year":"2023","series-title":"The Sanford guide to antimicrobial therapy","author":"Gilbert","key":"10.1016\/j.ijantimicag.2024.107345_bib0006"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0007","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1378\/chest.116.4.984","article-title":"The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine","volume":"116","author":"Malone","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijid.2020.01.010","article-title":"Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy","volume":"92","author":"Bue","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijid.2018.01.008","article-title":"Characteristics and factors associated with nosocomial pneumonia among patients undergoing continuous renal replacement therapy (CRRT): a case-control study","volume":"68","author":"Zuo","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0010","first-page":"426","article-title":"Drug dosing in continuous renal replacement therapy","volume":"32","author":"Li","year":"2012","journal-title":"Chin J Pract Intern Med"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0011","first-page":"39","article-title":"Effects of renal replacement therapy on antimicrobial therapy","volume":"8","author":"Vossen","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01824-17","article-title":"Validation of cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China","volume":"62","author":"Yu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0013","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0014","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.clinthera.2015.03.015","article-title":"Pharmacokinetic properties and tolerability of cycloserine following oral administration in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose 3-way crossover study","volume":"37","author":"Zhou","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2024.107345_bib0015","first-page":"867","article-title":"Expert consensus on the therapeutic drug monitoring of anti-tuberculosis drugs","volume":"43","year":"2021","journal-title":"Chin J Antituberc"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:55:05Z","timestamp":1730735705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0924857924002619"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107345","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and potential solutions for cycloserine dosing in patients with sepsis undergoing continuous renal replacement therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107345"}}